Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setmelanotide in LEPR deficiency obesity
2017-002005-36Phase 3Completed
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Jul 2017
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in leptin receptor deficiency and obesity comparing Open-label setmelanotide with Withdrawal placebo (2 arms). Primary endpoint: Proportion of patients meeting body weight response criterion at 1 year. Started Jul 2017; status: completed.
02
Drugs
setmelanotide
03
Conditions
leptin receptor deficiencyobesity
Beyond the preview
Go deeper on 2017-002005-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002005-36.